Clinical Trial Update: Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update of 125 mg/day oral azimilide in patients with implantable cardioverter defibrillators, reporting safety data from a completed st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Arrhythmias

Drugs mentioned

• Azimilide (azimilide)

Snippet

Sponsor: Forest Laboratories | Conditions: Arrhythmias | Phase 3 | Status: COMPLETED